Summary by Moomoo AI
On January 9, 2024, Panbela Therapeutics, Inc. received comments from the United States Securities and Exchange Commission (SEC) regarding its Registration Statement on Form S-1, which was initially filed on January 4, 2024. The SEC conducted a limited review and requested amendments to the registration statement, specifically asking Panbela Therapeutics to quantify the volume of Class E, Class F, and Pre-Funded Warrants on the cover page and to disclose the termination date of the offering. The SEC reminded the company of its responsibility for the accuracy and adequacy of disclosures. Panbela Therapeutics, which has engaged Roth Capital Partners as its placement agent in a best efforts offering, is expected to respond by amending the registration statement and providing the requested information. The SEC indicated that further comments may follow after reviewing the amendments and responses provided by Panbela Therapeutics.
